3. Deadlines

A. Applications shall be considered as meeting a deadline if they are either:

1. Received at the above address on or before the deadline date; or
2. Sent on or before the deadline date to the above address, and received in time for the review process. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be accepted as proof of timely mailing.)

B. Applications which do not meet the criteria in 3.A.1. or 3.A.2. above are considered late applications. Late applications will not be considered in the current competition and will be returned to the applicant.

Where to Obtain Additional Information

To receive additional written information call (404) 332–4561. You will be asked to leave your name, address and phone number and will need to refer to Announcement 565. You will receive a complete program description, information on application procedures, and application forms.

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from Georgia L. Jang, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Mailstop E13, Atlanta, GA 30305, telephone (404) 842–6814. Programmatic technical assistance may be obtained from Roy M. Fleming, Sc.D., Associate Director for Grants, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Building 1, Room 3053, Mailstop D30, Atlanta, GA 30333, telephone (404) 639–3343.

Please refer to Announcement 565 when requesting information and submitting an application.

Potential applicants may obtain a copy of ''Healthy People 2000'' (Full Report: Stock No. 017–001–00474–0) or ''Healthy People 2000 (Summary Report, Stock No. 017–001–00473–1) referenced in the ''Introduction'' through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325, telephone (202) 512–1800.

Dated: May 12, 1995.

Diane D. Porter,

Acting Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–12201 Filed 5–17–95; 8:45 am]

BILLING CODE 4163–19–P

Food and Drug Administration

[Docket No. 95N–0123]

Drug Export; Revia™ (Naltrexone Hydrochloride (HCl)) 50 Milligrams (mg) Film-Coated Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Dupont Merck has filed an application requesting approval for the export of the human drug Revia™ (naltrexone HCl) 50 mg film-coated tablets to Germany.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug Evaluation and Research (HFD–310), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20857, 301–594–3150.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Dupont Merck, Dupont Merck Plaza, Maple Run, Centre Rd., Wilmington, DE 19805, has filed an application requesting approval for the export of the human drug Revia™ (naltrexone HCl) 50 mg film-coated tablets to Germany. The firm holds an approved new drug application for an uncoated tablet, however, this application is for a new film-coated tablet formulation. This product is used as an adjunctive treatment of opioid dependence in detoxified, formerly opioid dependent individuals, and in a proposed indication as an adjunctive treatment for individuals with alcohol dependence undergoing psychosocial treatment programs. The application was received and filed in the Center for Drug Evaluation and Research on April 17, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by May 30, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: May 4, 1995.

Gayle R. Dolecek,

Acting Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 95–12177 Filed 5–17–95; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

National Institute of Dental Research; Notice of Meeting of NIDR Board of Scientific Counselors

Pursuant to Pub. L. 92–463, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Dental Research (NIDR), on June 7–9, 1995, in the Natcher Building, Conference Room A, National Institutes of Health, Bethesda, Maryland. The meeting will be open to the public from 8:55 a.m. to recess on June 8 and from

9:45 a.m. to 11:00 a.m. on June 9 for program and poster presentations. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in sec. 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92–463, the meeting will be closed to the public from 6:00 p.m. until recess on June 7 and from 12:30 p.m. until adjournment on June 9 for the review, discussion, and evaluation of individual programs and projects conducted by the NIDR, including consideration of personnel qualifications and performance, the competence of individual investigators, and similar items, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mr. Brent Jaquet, Director, Office of Planning, Evaluation, and Communications, NIDR, NIH, Building 31, Room 2C34, Bethesda, Maryland 20892 (telephone: (301) 496–6705) will provide summary of the meeting, roster of committee members and substantive program information. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary listed above in advance of the meeting.

Dated: May 11, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–12192 Filed 5–17–95; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive License: Polysaccharide-Protein Conjugates

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice is in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Number 5,204,098 entitled ''Polysaccharide-Protein Conjugates'' and related foreign patent applications to Connaught Laboratories, Inc., of Swiftwater, Pennsylvania. The patent rights in this invention have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license will be limited to the field of typhoid vaccines and typhoid Vi-protein conjugates for the prevention of typhoid fever in humans. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent describes conjugates of bacterial capsular polysaccharides and carrier proteins, and methods of synthesis, wherein the polysaccharide and protein are linked through a thio derivative of a carboxyl group found on the polysaccharide. The conjugates are useful as vaccines for prevention of disease caused by infection by the bacterial species from which the capsular polysaccharide is derived.

ADDRESSES: Requests for a copy of this patent, inquiries, comments and other materials relating to the contemplated license should be directed to: Robert Benson, Patent Advisor, Office of Technology Transfer, National Institutes of Health, 6011 Executive Blvd., Box 13, Rockville, MD 20852. Telephone: (301) 496–7056, X267; Facsimile: (301) 402–0220. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before July 17, 1995, will be considered.

Dated: May 5, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 95–12193 Filed 5–17–95; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Community Planning and Development

[Docket No. N–95–3888; FR–3886–N–04]

Homeownership of Single Family Homes Program (HOPE 3); Notice of Fund Availability: Notice of Extension of Application Deadline for Applicants in Oklahoma

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice of further extension of deadline.

SUMMARY: This notice provides a further extension of the application submission deadline for the HOPE 3 applicants affected by the destruction of HUD's Office in Oklahoma City, Oklahoma. An extension of this deadline was already published on May 9, 1995, but because of a typographical error, the new deadline was misstated. In addition, because of the destruction of documents due to the Oklahoma City explosion, any applicant that has already submitted an application under the HOPE 3 NOFA to HUD's Office in Oklahoma City should resubmit a copy of its application to the Fort Worth Office, as provided in this notice.

DATES: The application deadline for applicants from Oklahoma will be May 19, 1995, 4:30 Central Time.

FOR FURTHER INFORMATION CONTACT: For applicants in Oklahoma, contact Will Williamson, HOPE 3 Coordinator, phone (817) 885–5887. For general information about this notice, contact Salvatore Sclafani, Program Analyst, Office of Community Planning and Development, Department of Housing and Urban Development, Room 7208, 451 Seventh Street, SW., Washington, DC 20410, telephone (202) 708–1283; or (202) 708–2565 (TDD). (These telephone numbers are not toll-free.)

SUPPLEMENTARY INFORMATION: Because of the destruction of the HUD Office in Oklahoma City, Oklahoma, on April 19, 1995, the Department published a notice in the **Federal Register** (60 FR 24646, May 9, 1995) to extend the deadline for the submission of applications for certain programs, including the HOPE 3 Program. The Notice extended the application deadline for HOPE 3 applicants within the State of Oklahoma from April 25, 1995, to May 8, 1995. Because of a typographical error, the fact that some documents may be unaccounted for due to the destruction of documents in the Oklahoma City explosion, and the time required for applicants to resubmit copies of HOPE 3 applications to the Fort Worth Office, the Department has decided to provide an additional extension of time—to May 19, 1995—for HOPE 3 applicants in the State of Oklahoma. Any applicant under the HOPE 3 NOFA that has already submitted an application to the Oklahoma City office is directed to resubmit its application to HUD's Fort Worth Office, as indicated below in this notice. Photocopies of all of the documentation and materials as originally submitted to the Oklahoma City Office will be acceptable, as long as the applicant also provides proof of submission (e.g., postal or Federal Express receipt). Completed applications may not be submitted by fax.